CD44‐Targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3‐Mediated Pyroptosis
Authors:
- 15 January 2023
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (11) , e2202228
Abstract
Liver fibrosis is a progressive pathological process induced by various stimuli and may progress to liver cirrhosis and cancer. Forsythiaside A (FA) is an active ingredient extracted from traditional Chinese medicine Forsythiae Fructus and has prominent hepatoprotective activities. However, the unsatisfactory pharmacokinetic properties restrict its clinical application. In this study, the nanocarrier of CD44‐specific ligand Hyaluronic acid (HA)‐modified milk‐derived exosomes (mExo) encapsulated with FA (HA‐mExo‐FA) is developed. As a result, HA modification could deliver drug‐loaded exosomes to the target cells and form a specific ligand‐receptor interaction with CD44, thus improving the anti‐liver fibrosis effect of FA. In vitro findings indicate that HA‐mExo‐FA could inhibit TGF‐β1‐induced LX2 cell proliferation, reduce α‐SMA and collagen gene and protein levels, and promote the apoptosis of activated LX2 cells. In vivo results demonstrate that HA‐mExo‐FA could improve liver morphology and function changes in zebrafish larvae. The anti‐liver fibrosis mechanism of HA‐mExo‐FA may be attributed to the inhibition of NLRP3‐mediated pyroptosis. In addition, the effect of HA‐mExo‐FA on TAA‐induced increase in NLRP3 production is attenuated by NLRP3 inhibitor MCC950. Collectively, this study demonstrates the promising application of HA‐mExo‐FA in drug delivery with high specificity and provides a powerful and novel delivery platform for liver fibrosis therapy.Keywords
Funding Information
- Ministry of Education
- National Natural Science Foundation of China (81891012, 81630101, U19A2010)
This publication has 54 references indexed in Scilit:
- Corona-Directed Nucleic Acid Delivery into Hepatic Stellate Cells for Liver Fibrosis TherapyACS Nano, 2015
- Zebrafish as model organisms for studying drug‐induced liver injuryBritish Journal of Clinical Pharmacology, 2014
- Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancerExpert Review of Anticancer Therapy, 2014
- NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in miceHepatology, 2013
- Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell modelsActa Pharmacologica Sinica, 2012
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Inflammasomes in health and diseaseNature, 2012
- APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver developmentDevelopmental Biology, 2008
- Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in ratsToxicology and Applied Pharmacology, 2007
- Stages of embryonic development of the zebrafishDevelopmental Dynamics, 1995